Menu Back to Biosimilars-Conference


September 20-21: Conference

DIA is offering both a live in-person conference or an On Demand Library for the Biosimilars Conference that allows you to view all the session recordings from the comfort of your own home/office at your own pace. Upon registration, please indicate via the check box which avenue you are registering for: in-person or on demand.

The Biosimilars Price Competition and Innovation Act (BCPIA) created a biosimilars approval pathway in the US with the goal of increasing access to safe, effective, and cost effective biological treatment options for patients. To date, significant progress has been made in the science and regulation of biosimilar development and approval but barriers still exist to a robust biosimilars market. The current ongoing challenges are legal complications to the launch of a biosimilar, the persistence of misinformation and disparagement, and delays in the creation of policies that increase patient access. The challenges have been and continue to be complex, interrelated, and best addressed by stakeholder collaboration, not only within the US but across global regions.

Biosimilars remain of interest due to for their potential to provide cost savings to patients, reducing overall burden on the system, and possible improvement over the competition. To increase their market share, stakeholders are now focusing on streamlining biosimilars development, meeting ongoing manufacturing challenges, addressing pricing issues, and educating prescriber and patients on the benefits of biosimilars. At the DIA 2022 Biosimilars Conference, manufacturers, regulators, payers, prescribers, and patients will come together to discuss factors that influence biosimilar development and access and to share perspectives on what success and equilibrium will look like. They’ll apply the newest thinking and relevant learnings from global regions to build strategies for continuing the growth of the biosimilars market and bringing these important biologic therapies – and cost savings - to patients.

While we develop our 2022 Agenda, please take a look at the 2021 final agenda

Who should attend?

Professionals involved in:
  • Biosimilar/Biologic Pharmaceutical Research
  • Biomedical Product Development and Manufacturing
  • Chemistry, Manufacturing and Controls
  • Regulatory Affairs
  • Clinical and Nonclinical Research
  • Biostatistics and Data Management
  • Business Development
  • Marketing and Commercialization for biosimilars
  • Medical Communications/MSLs
  • Patient Advocacy/Patient Support Programs
  • Health and medical care across therapeutic disciplines
  • Health Education
  • Provision of prescription products
  • Development and management of prescription product formularies
  • Development and management of prescription benefit plans
  • Quality management

Digital Learning Catalog

DIA Learning: eLearning Soultions